Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
Be 'active' in the market while NOT being tied to your desk.
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| GILD | Gilead Sciences, Inc. | 0.55% | 73.74 | 0.9% | $598.99m | |
| CELG | Celgene Corporation | -0.84% | 129.19 | 1.1% | $425.21m | |
| AMGN | Amgen Inc. | -0.63% | 169.00 | 1.1% | $397.19m | |
| BIIB | Biogen Inc. | -1.42% | 282.64 | 1.2% | $346.45m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -0.31% | 477.15 | 2.7% | $319.17m | |
| VRTX | Vertex Pharmaceuticals Incorporated | -1.43% | 153.25 | 1.9% | $227.49m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.83% | 135.67 | 1.9% | $211.59m | |
| ILMN | Illumina, Inc. | -0.59% | 193.62 | 3.5% | $208.34m | |
| KITE | Kite Pharma, Inc. | 1.63% | 138.17 | 16.1% | $135.10m | |
| INCY | Incyte Corporation | -0.17% | 123.65 | 2.6% | $130.04m | |
| CLVS | Clovis Oncology, Inc. | -0.68% | 71.61 | 18.0% | $125.25m | |
| TSRO | TESARO, Inc. | -0.18% | 120.40 | 14.7% | $124.85m | |
| A | Agilent Technologies, Inc. | -0.30% | 62.77 | 1.5% | $122.45m | |
| BMRN | BioMarin Pharmaceutical Inc. | -0.07% | 81.40 | 4.4% | $105.16m | |
| SRPT | Sarepta Therapeutics, Inc. | -2.38% | 36.07 | 19.8% | $88.80m |
Company Profile
Biogen, Inc. is a global biotechnology company, which focuses on discovering, developing, manufacturing and delivering therapies for neurological, autoimmune and hematologic disorders. Its products include AVONEX, PLEGRIDY, TECFIDERA, TYSABRI, and FAMPYRA for multiple sclerosis, ALPROLIX for hemophilia B and ELOCTATE for hemophilia A. The company also collaborates on the development and commercialization of RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and other conditions and share profits and losses for GAZYVA which is approved for the treatment of chronic lymphocytic leukemia. Biogen was founded by Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.